Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Mural Oncology plc

We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

	Dec '21	Dec '22	Dec '23
account payables	10.59M -	2.97M 71.98%	5.97M 101.38%
accumulated other comprehensive income loss
cash and cash equivalents	-25.31M -	-19.39M 23.39%	270.85M 1,497.15%
cash and short term investments	-25.31M -	-19.39M 23.39%	270.85M 1,497.15%
common stock			167K -
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			150K -
long term debt	19.39M -	13.54M 30.15%	8.91M 34.20%
long term investments
net debt	50.61M -	38.77M 23.39%	-255.84M 759.87%
net receivables			5.55M -
other assets
other current assets	2.04M -	1.83M 10.25%	787K 56.99%
other current liabilities	16.74M -	32.75M 95.63%	16.95M 48.26%
other liabilities
other non current assets			258K -
other non current liabilities	356K -	304K 14.61%
othertotal stockholders equity			294.51M -
preferred stock
property plant equipment net	30.87M -	28.93M 6.28%	24.15M 16.53%
retained earnings			-30.86M -
short term debt	5.92M -	5.84M 1.28%	6.10M 4.35%
short term investments
tax assets
tax payables
total assets	35.11M -	33.75M 3.87%	301.75M 794.06%
total current assets	4.24M -	4.82M 13.64%	277.34M 5,657.46%
total current liabilities	33.25M -	41.56M 25.00%	29.02M 30.18%
total debt	25.31M -	19.39M 23.39%	15.01M 22.58%
total investments
total liabilities	52.99M -	55.41M 4.56%	37.93M 31.55%
total liabilities and stockholders equity	35.11M -	33.75M 3.87%	301.75M 794.06%
total non current assets	30.87M -	28.93M 6.28%	24.41M 15.64%
total non current liabilities	19.74M -	13.85M 29.87%	8.91M 35.64%
total stockholders equity	-17.88M -	-21.66M 21.13%	263.82M 1,318.22%

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

21/11 21:00

Market Cap

51.45M

Beta: -

Volume Today

98.55K

Avg: -

Preview